MRNA Jul 2024 110.000 call
- Barrons.com
The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why.
What began Tuesday as a puzzling dip in shares of the biotech Moderna accelerated into a larger selloff Wednesday. The stock was down 5.5% Wednesday morning, bringing the stocks losses to 13% since the market closed on Friday. The stumble in Moderna share price, Barron’s wrote Tuesday, comes as investors await updates on three key areas: the company’s experimental cancer vaccine being developed with Merck ; the respiratory syncytial virus vaccine the Food and Drug Administration is expected to approve in the next few days, and the avian flu virus circulating in domestic cattle.
- Zacks
Nasdaq Tops 17K: 5 Best-Performing Stocks in ETF YTD
The Nasdaq Composite Index topped the 17,000 level for the first time. We have highlighted five best-performing stocks of QQQ this year that led the way higher in the portfolio.
- Barrons.com
Moderna Stock Is Having Another Very Bad Day. Here’s Why.
The stock’s drop comes as Moderna awaits important developments involving its experimental cancer treatment, a new respiratory vaccine, and a possible avian flu vaccine under development.Read the full ...
